CL2024000327A1 - Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer - Google Patents
Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncerInfo
- Publication number
- CL2024000327A1 CL2024000327A1 CL2024000327A CL2024000327A CL2024000327A1 CL 2024000327 A1 CL2024000327 A1 CL 2024000327A1 CL 2024000327 A CL2024000327 A CL 2024000327A CL 2024000327 A CL2024000327 A CL 2024000327A CL 2024000327 A1 CL2024000327 A1 CL 2024000327A1
- Authority
- CL
- Chile
- Prior art keywords
- pi3k
- inhibit
- methods
- compounds
- alpha isoform
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 title abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 abstract 2
- 101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 abstract 2
- 108030003690 Phosphatidylinositol-4,5-bisphosphate 3-kinases Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231156P | 2021-08-09 | 2021-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000327A1 true CL2024000327A1 (es) | 2024-08-09 |
Family
ID=83188497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000327A CL2024000327A1 (es) | 2021-08-09 | 2024-02-02 | Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20240343728A1 (enExample) |
| EP (1) | EP4363414A1 (enExample) |
| JP (1) | JP2024533975A (enExample) |
| KR (1) | KR20240051953A (enExample) |
| CN (1) | CN118159534A (enExample) |
| AU (1) | AU2022325819A1 (enExample) |
| CA (1) | CA3227902A1 (enExample) |
| CL (1) | CL2024000327A1 (enExample) |
| CO (1) | CO2024000448A2 (enExample) |
| CR (1) | CR20240045A (enExample) |
| DO (1) | DOP2024000019A (enExample) |
| EC (1) | ECSP24008488A (enExample) |
| GE (1) | GEAP202416449A (enExample) |
| IL (1) | IL310588A (enExample) |
| JO (1) | JOP20240020A1 (enExample) |
| MA (1) | MA63885B1 (enExample) |
| MX (1) | MX2024000708A (enExample) |
| PE (1) | PE20240652A1 (enExample) |
| UA (1) | UA130857C2 (enExample) |
| WO (1) | WO2023018636A1 (enExample) |
| ZA (1) | ZA202401094B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025538147A (ja) | 2022-11-02 | 2025-11-26 | ペトラ・ファーマ・コーポレイション | 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化 |
| WO2024233256A1 (en) | 2023-05-05 | 2024-11-14 | Eli Lilly And Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
| WO2025036439A1 (en) * | 2023-08-16 | 2025-02-20 | Laekna Pharmaceutical Ningbo Co., Ltd. | Multicyclic compounds and their use as pi3k alpha inhibitors |
| IL330261A (en) * | 2023-12-27 | 2026-08-01 | Genesis Molecular Ai Inc | Cancer treatment methods |
| WO2025201503A1 (en) * | 2024-03-28 | 2025-10-02 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2026060099A1 (en) * | 2024-09-12 | 2026-03-19 | Kymathera, Inc. | Selective pi3k inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0515025D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| WO2009001089A1 (en) * | 2007-06-26 | 2008-12-31 | Ucb Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
| CA2755285C (en) * | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibitors of pi3 kinase |
| DE102009043260A1 (de) * | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| US9062055B2 (en) * | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| EA201692557A1 (ru) * | 2014-07-04 | 2017-05-31 | Люпин Лимитед | Хинолизиноновые производные в качестве ингибиторов pi3k |
| CN111909173B (zh) * | 2015-07-02 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法 |
| WO2017221272A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of idelalisib |
| WO2021001431A1 (en) * | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer |
-
2022
- 2022-08-08 MA MA63885A patent/MA63885B1/fr unknown
- 2022-08-08 CN CN202280062281.6A patent/CN118159534A/zh active Pending
- 2022-08-08 CR CR20240045A patent/CR20240045A/es unknown
- 2022-08-08 UA UAA202400583A patent/UA130857C2/uk unknown
- 2022-08-08 GE GEAP202416449A patent/GEAP202416449A/en unknown
- 2022-08-08 EP EP22764505.8A patent/EP4363414A1/en active Pending
- 2022-08-08 KR KR1020247007455A patent/KR20240051953A/ko active Pending
- 2022-08-08 US US18/293,823 patent/US20240343728A1/en active Pending
- 2022-08-08 JP JP2024506896A patent/JP2024533975A/ja active Pending
- 2022-08-08 AU AU2022325819A patent/AU2022325819A1/en active Pending
- 2022-08-08 MX MX2024000708A patent/MX2024000708A/es unknown
- 2022-08-08 CA CA3227902A patent/CA3227902A1/en active Pending
- 2022-08-08 IL IL310588A patent/IL310588A/en unknown
- 2022-08-08 WO PCT/US2022/039674 patent/WO2023018636A1/en not_active Ceased
- 2022-08-08 PE PE2024000156A patent/PE20240652A1/es unknown
-
2024
- 2024-01-18 CO CONC2024/0000448A patent/CO2024000448A2/es unknown
- 2024-02-01 EC ECSENADI20248488A patent/ECSP24008488A/es unknown
- 2024-02-01 JO JOJO/P/2024/0020A patent/JOP20240020A1/ar unknown
- 2024-02-02 CL CL2024000327A patent/CL2024000327A1/es unknown
- 2024-02-02 ZA ZA2024/01094A patent/ZA202401094B/en unknown
- 2024-02-02 DO DO2024000019A patent/DOP2024000019A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202401094B (en) | 2025-05-28 |
| IL310588A (en) | 2024-04-01 |
| ECSP24008488A (es) | 2024-05-31 |
| EP4363414A1 (en) | 2024-05-08 |
| CN118159534A (zh) | 2024-06-07 |
| JOP20240020A1 (ar) | 2024-02-01 |
| UA130857C2 (uk) | 2026-05-27 |
| CA3227902A1 (en) | 2023-02-16 |
| JP2024533975A (ja) | 2024-09-18 |
| CR20240045A (es) | 2024-02-20 |
| KR20240051953A (ko) | 2024-04-22 |
| PE20240652A1 (es) | 2024-04-04 |
| WO2023018636A1 (en) | 2023-02-16 |
| CO2024000448A2 (es) | 2024-02-15 |
| DOP2024000019A (es) | 2024-03-15 |
| MA63885B1 (fr) | 2025-01-31 |
| AU2022325819A1 (en) | 2024-02-29 |
| GEAP202416449A (en) | 2024-04-25 |
| MA63885A1 (fr) | 2024-09-30 |
| US20240343728A1 (en) | 2024-10-17 |
| MX2024000708A (es) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003691A1 (es) | Derivados de la urea que pueden ser utilizados para tratar el cáncer | |
| DOP2024000019A (es) | Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer | |
| CL2022002919A1 (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
| CR20220584A (es) | Inhibidores de kras tricíclicos fusionados | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
| UY38742A (es) | Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida | |
| ECSP088828A (es) | 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r | |
| ECSP13012752A (es) | Imidazopiridazinas sustituidas | |
| MX2022014924A (es) | Moduladores de il-17a. | |
| CO2022018636A2 (es) | Moduladores de il-17a | |
| CL2021003568A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198) | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| UY39061A (es) | Inhibidores macrocíclicos de rip2-cinasa | |
| CO2022014886A2 (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52 | |
| CL2025002448A1 (es) | Compuestos inhibidores de quinasa dependientes de ciclina (cdk2). | |
| MX2025004073A (es) | Métodos para tratar el cáncer | |
| UY30880A1 (es) | 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones | |
| UY39819A (es) | Métodos para tratar el cáncer | |
| MX2025004911A (es) | Terapia de combinacion para tratar el cancer | |
| AR126147A1 (es) | Derivados de urea para tratar el cáncer | |
| MX2021008748A (es) | Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias. | |
| CO2019001967A2 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR123760A1 (es) | Métodos para tratar el cáncer | |
| AR123576A1 (es) | Métodos para tratar el cáncer |